HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 57432

HXB2 Location  Gag(216-224)   Gag Epitope Map
View variants at this location
Epitope HPVHAGPVA   Epitope Alignment
Variants
HPVqAGPVA   non-susceptible form; susceptible form
HPVHAGPiA   non-susceptible form; susceptible form
HPVHAGPip   non-susceptible form; susceptible form
HPVHAGPVp   non-susceptible form; susceptible form
HPaHAGPVA   non-susceptible form; susceptible form
HPVaAGPVA   non-susceptible form; susceptible form
HPVHvGPVA   non-susceptible form; susceptible form
HPVHAaPVA   non-susceptible form; susceptible form
Epitope Name HA9
Species (MHC/HLA human(B7 supertype)

Variant Details

Showing all: 8 variant(s).


Variant ID.  2472
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVqAGPVA
Mutations H/Q
Epitope Location H4Q
HXB2 Location H219Q
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVqAGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2473
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHAGPiA
Mutations V/I
Epitope Location V8I
HXB2 Location V223I
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPiA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2474
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHAGPip
Mutations V/I A/P
Epitope Location V8I A9P
HXB2 Location V223I A224P
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPip, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2475
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHAGPVp
Mutations A/P
Epitope Location A9P
HXB2 Location A224P
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPVp, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2476
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPaHAGPVA
Mutations V/A
Epitope Location V3A
HXB2 Location V218A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPaHAGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2477
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVaAGPVA
Mutations H/A
Epitope Location H4A
HXB2 Location H219A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype D
Method CD8 T-cell Elispot - IFNy
Note Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVaAGPVA, but cells encountering this variant were not susceptible in patients 2632 (African female, experienced some treatment, autologous virus Clade A1) and 2295 (Caucasian female, experienced some treatment, autologous virus Clade C).


Variant ID.  2478
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHvGPVA
Mutations A/V
Epitope Location A5V
HXB2 Location A220V
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHvGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2479
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHAaPVA
Mutations G/A
Epitope Location G6A
HXB2 Location G221A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAaPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

References

Hoof2010 Ilka Hoof, Carina L. Pérez, Marcus Buggert, Rasmus K. L. Gustafsson, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. J Immunol, 184(9):5383-5391, 1 May 2010. PubMed ID: 20363973. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health